BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumar SS, Binu A, Devan AR, Nath LR. Mucus targeting as a plausible approach to improve lung function in COVID-19 patients. Med Hypotheses 2021;156:110680. [PMID: 34592563 DOI: 10.1016/j.mehy.2021.110680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Prasher P, Sharma M, Singh SK, Gulati M, Jha NK, Gupta PK, Gupta G, Chellappan DK, Zacconi F, de Jesus Andreoli Pinto T, Chan Y, Liu G, Paudel K, Hansbro PM, George Oliver BG, Dua K. Targeting mucus barrier in respiratory diseases by chemically modified advanced delivery systems. Chem Biol Interact 2022;:110048. [PMID: 35932910 DOI: 10.1016/j.cbi.2022.110048] [Reference Citation Analysis]
2 Yu S, Qian L, Ma J. Genetic alterations, RNA expression profiling and DNA methylation of HMGB1 in malignancies. J Cell Mol Med 2022. [PMID: 35765707 DOI: 10.1111/jcmm.17454] [Reference Citation Analysis]
3 Manhas RS, Tiwari H, Noor M, Ahmed A, Vishwakarma J, Tripathi RBM, Ramachandran R, Madishetti S, Mukherjee D, Chaubey A, Nargotra A. Setomimycin as a potential molecule for COVID‑19 target: in silico approach and in vitro validation. Mol Divers 2022. [PMID: 35622309 DOI: 10.1007/s11030-022-10441-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Thomas P, Baldwin C, Beach L, Bissett B, Boden I, Cruz SM, Gosselink R, Granger CL, Hodgson C, Holland AE, Jones AY, Kho ME, van der Lee L, Moses R, Ntoumenopoulos G, Parry SM, Patman S. Physiotherapy management for COVID-19 in the acute hospital setting and beyond: an update to clinical practice recommendations. J Physiother 2021:S1836-9553(21)00139-9. [PMID: 34953756 DOI: 10.1016/j.jphys.2021.12.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]